AKERO THERAPEUTICS INC (1AKRO.MI) Stock Overview
Europe - BIT:1AKRO - US00973Y1082 - Common Stock
1AKRO.MI Key Statistics, Chart & Performance
The current stock price of 1AKRO.MI is 45.71 EUR.
1AKRO.MI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 4AB.DE | ABBVIE INC | 21.43 | 345.19B | ||
| AMG.DE | AMGEN INC | 13.35 | 135.02B | ||
| 1GILD.MI | GILEAD SCIENCES INC | 15.87 | 131.38B | ||
| GIS.DE | GILEAD SCIENCES INC | 15.51 | 128.40B | ||
| VX1.DE | VERTEX PHARMACEUTICALS INC | 25.3 | 94.65B | ||
| ARGX.BR | ARGENX SE | 95.51 | 43.75B | ||
| 1AE.DE | ARGENX SE | 94.35 | 43.22B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 21.70B | ||
| IDP.DE | BIOGEN INC | 9.4 | 19.01B | ||
| 0QF.DE | MODERNA INC | N/A | 9.00B | ||
| 1MRNA.MI | MODERNA INC | N/A | 8.85B | ||
| 1EXEL.MI | EXELIXIS INC | 17.15 | 8.26B |
Related stock screener links
About 1AKRO.MI
Company Profile
Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The company is headquartered in South San Francisco, California and currently employs 67 full-time employees. The company went IPO on 2019-06-20. Efruxifermin (EFX), its lead product candidate for MASH, is being evaluated in three ongoing Phase 3 studies: SYNCHRONY Outcomes in patients with compensated cirrhosis (F4) due to MASH, SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, and SYNCHRONY Real-World in patients with MASH (F1-F4). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body.
Company Info
AKERO THERAPEUTICS INC
601 Gateway Boulevard, Suite 350
South San Francisco CALIFORNIA US
Employees: 67
Phone: 16504876488
AKERO THERAPEUTICS INC / 1AKRO.MI FAQ
Can you describe the business of AKERO THERAPEUTICS INC?
Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The company is headquartered in South San Francisco, California and currently employs 67 full-time employees. The company went IPO on 2019-06-20. Efruxifermin (EFX), its lead product candidate for MASH, is being evaluated in three ongoing Phase 3 studies: SYNCHRONY Outcomes in patients with compensated cirrhosis (F4) due to MASH, SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, and SYNCHRONY Real-World in patients with MASH (F1-F4). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body.
What is the current price of 1AKRO stock?
The current stock price of 1AKRO.MI is 45.71 EUR.
What is the dividend status of AKERO THERAPEUTICS INC?
1AKRO.MI does not pay a dividend.
What is the ChartMill technical and fundamental rating of 1AKRO stock?
1AKRO.MI has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists 1AKRO stock?
1AKRO.MI stock is listed on the Euronext Milan exchange.
Can you provide the ownership details for 1AKRO stock?
You can find the ownership structure of AKERO THERAPEUTICS INC (1AKRO.MI) on the Ownership tab.
1AKRO.MI Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to 1AKRO.MI.
1AKRO.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to 1AKRO.MI. 1AKRO.MI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
1AKRO.MI Financial Highlights
Over the last trailing twelve months 1AKRO.MI reported a non-GAAP Earnings per Share(EPS) of -3.27. The EPS decreased by -11.44% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -25.6% | ||
| ROE | -27.68% | ||
| Debt/Equity | 0.02 |